SAB Biotherapeutics, Inc. Warrant closed at $0.01 on Sep 28, down 4.10%, 70.6% below its highest close since Oct 25. Volume of 10.8K shares was 0.39× its 20-day average (below normal).
Split-adjusted performance: -44.9% over one month, -48.9% over six months.
Short interest was 765 shares at the Sep 15 settlement, down 88.5% from the prior report (1.0 days to cover).
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients.
What sector is SABSW in?
Healthcare, in the Biotechnology industry.
About SAB Biotherapeutics, Inc. Warrant
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
HQ: Miami Beach, FL86 employeesListed Oct 22, 2021sab.bio
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
